DSP-7888: Preliminary Ph I data

Preliminary data from 12 patients with low- or high-risk MDS in the Phase I portion of an open-label, Japanese Phase I/II trial showed that intradermal DSP-7888 every 2-4 weeks was well tolerated and ...